MON, PWRM, NHPR, PKI, DOX Stock Market Report from Stock.PR.com

FREE Daily Stock Alerts From Stock-PR.com

Monsanto Co. (NYSE:MON) recently announced that its Board of Directors declared a quarterly dividend on its common stock of 28 cents per share. The dividend is payable on July 29, 2011 to shareowners of record on July 8, 2011. It relates to the third quarter of the company’s 2011 fiscal year.

Monsanto Company, together with its subsidiaries, provides agricultural products for farmers in the United States and internationally. It operates in two segments, Seeds and Genomics, and Agricultural Productivity.

************

Power3 Medical Products, Inc. (PWRM) is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).

People who have Alzheimer’s disease have abnormal deposits of a protein called beta-amyloid. Abnormal structures called plaque are formed from a combination of destroyed nerve cells and the beta-amyloid. Tangles of nerve fibers are formed from abnormal nerve cells along with a type of protein called TAU. As the tangles and plaque develop, nerve cell connections are reduced. The elimination of nerve cell connections causes damage to certain pathways in the brain. These pathways are essential for thinking, learning, and memory.

People who have Alzheimer’s disease have smaller brains than the normal population. They also have lower amounts of a neurotransmitter called acetylcholine. This chemical is essential for memory and thinking.

The NuroPro Blood Test is Power3 Medical’s diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease. Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.

The NuroPro Test is currently in the development stages. The company has completed proof-of-concept and clinical validation studies, with results exceeding expectations. Currently, Power3 Medical has commenced a three hundred patient clinical validation study of its NuroPro diagnostic test for Alzheimer’s disease and Parkinson’s disease.

Power3 Medical Products, Inc website: http://www.power3medical.com.

************

National Health Partners, Inc. is a national healthcare savings organization that provides discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called “CARExpress.” CARExpress is one of the largest networks of hospitals, doctors, dentists, pharmacists and other healthcare providers in the country and is comprised of over 1,000,000 medical professionals that belong to such PPOs as CareMark and Aetna. The company’s primary target customer group is the 47 million Americans who have no health insurance of any kind. The company’s secondary target customer group includes the millions of Americans who lack complete health insurance coverage.

National Health Partners, Inc., announced the recent signing of two new significant marketing agreements. These two clients provide very different opportunities and continue to expand the reach of CARExpress into new marketplaces.

By launching their own unique internet marketing program, the first group should be able to provide a widespread push into the on-line market to produce an excellent volume of new CARExpress sales into the pipeline. In addition, the second group offers a reach into the wholesale marketplace where CARExpress will be wrapped into other programs to enhance the value of the overall package to the consumer. They would consider this non-traditional business and a great opportunity to expand their reach as well as recognition of the CARExpress program nationwide.

The company plans to announce the rollout of these new marketing campaigns as well as several others over the next few weeks.

More about NHPR at www.nationalhealthpartners.com

************

PerkinElmer Inc. (NYSE:PKI) recently declared a regular quarterly dividend of $0.07 per share of common stock on June 9, 2011. This dividend is payable on August 12, 2011, to all shareholders of record at the close of business on July 22, 2011.

PerkinElmer, Inc. provides technology, services, and solutions to the diagnostics, research, environmental, safety and security, industrial and laboratory services markets. PerkinElmer has the portfolios of functional cellular science research technologies, as well as GPCR and kinase products used in researching approximately 75% of drug pathways.

************

Amdocs Ltd. (NYSE:DOX) recently announced enhancements to its Amdocs Multi-Play Smart Pack solution to strengthen customer support capabilities, improve operational efficiencies and allow greater flexibility for mid-tier and independent cable TV operators.

Amdocs Limited, through its subsidiaries, provides software and services to the communications, media, and entertainment industry service providers worldwide.

**********************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer). Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings Inc. (CRWE.OB) has received 3,000,000 shares of (144) restricted common stock from the company and 3,000,000 shares of free trading shares from a third party (PIERRE BESUCHET) for six months of advertisement services for National Health Partners Inc. (NHPR.OB).

**********************************************************

Sign Up For Free Stock Alerts At http://stock-pr.com/signup

**********************************************************

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.